Observational studyBMC pregnancy and childbirth2025
Impact of stopping Tenofovir disoproxil fumarate at various times on elevated postpartum ALT levels and breastfeeding in pregnant women with chronic hepatitis B: a prospective observational cohort study.
Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo investigate the impact of tenofovir disoproxil fumarate (TDF) withdrawal timing on elevated postpartum alanine aminotransferase (ALT) levels and breastfeeding in pregnant women who received TDF therapy to prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection.
methodsAll enrolled women began treatment with TDF during weeks 24-32 of pregnancy and were divided into three groups that stopped TDF at delivery (Group A), at 4 weeks postpartum (Group B), or at 12 weeks postpartum (Group C). The biochemical and virological markers of hepatitis B were regularly measured and compared. Binary logistic regression analysis was used to explore the risk factors of elevated ALT levels.
resultsElevated postpartum ALT levels were observed in 91 of the 160 patients, including 38 out of 59 (64.41%) in Group A, 27 out of 51 (52.94%) in Group B, and 26 out of 50 (54%) in Group C. The incidence of elevated ALT levels did not differ significantly among the three groups (P = 0.338). Moreover, there was no significant difference in the severity of elevated ALT levels among the three groups (P = 0.558). Binary logistic regression analysis showed that ALT at delivery was an independent risk factor for elevated ALT levels (odds ratio = 1.098, 95% confidence interval, 1.039-1.160, P = 0.001). ROC analysis identified ALT ≥ 23 U/L at delivery as the optimal cutoff (AUC = 0.703, 95% CI: 0.622-0.785) for predicting elevated postpartum ALT levels. Breastfeeding rates were significantly higher in Group A (79.66%) compared to Group B (25.49%) and Group C (42%), both P values = 0.000.
conclusionsWhen TDF is used to prevent MTCT of HBV, withdrawal timing did not significantly affect overall ALT elevation patterns. However, early TDF withdrawal at delivery was associated with higher breastfeeding rates, and mothers with ALT levels ≥ 23 U/L at delivery may benefit from extended postpartum antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.